Enanta Pharmaceuticals doses first patient in Phase 2b/3 RESOLVE trial of zelicapavir for RSV

Enanta Pharmaceuticals announced it dosed the first patient in its global Phase 2b/3 clinical trial RESOLVE, evaluating investigational drug zelicapavir in adults at high risk of severe outcomes from RSV. The company expects topline data from the Phase 2b portion in 2027.

Detected & updated continuously · Source: Nebula